BMO Capital raised its price target on Halozyme Therapeutics (NASDAQ: HALO) to $21.00 (from $19.00) while maintaining a Market Perform ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE